60 Degrees Pharmaceuticals Receives FDA Comments On Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required, Trial Planning And Execution To Proceed As Planned
60 Degrees Pharmicals收到美國食品藥品管理局對他非諾喹-巴貝斯蟲病臨床試驗方案的評論；無需進行實質性更改，試驗計劃和執行按計劃進行